 
                                Oncolytics Biotech
@oncolytics
Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells.
Contact company: bit.ly/371iOaq
ID: 25760403
http://www.oncolyticsbiotech.com 22-03-2009 01:29:42
1,1K Tweet
2,2K Takipçi
390 Takip Edilen
 
         
        New data from the GOBLET #ClinicalTrial presented with Arbeitsgemeinschaft Internistische Onkologie - AIO at #ASCO25 demonstrate how our investigational treatment #pelareorep, in combination with chemotherapy & a checkpoint inhibitor, activates immune responses in patients with #PDAC: bit.ly/4jdXDoL
 
                        
                    
                    
                    
                 
        We are headed to #BIO2025! Join our VP of Business Development, Christophe Degois, as he highlights how Oncolytics is partnering to transform #ImmunoOncology. Schedule a meeting with Christophe: bit.ly/3HvcMoF Biotechnology Innovation Organization
 
        We shared new data from the GOBLET study in collaboration with Arbeitsgemeinschaft Internistische Onkologie - AIO at #ASCO2025 showing how our candidate, #pelareorep, in combo with chemotherapy and a checkpoint inhibitor, activates immune responses in #PancreaticCancer patients: bit.ly/42VdW53
 
         
         
         
         
         
         
         
         
        This recent Targeted Oncology feature highlights survival data for our investigational immunotherapy #pelareorep and its potential in hard-to-treat cancers. The data support advancement of pelareorep into registration-enabling studies. Read the full article: bit.ly/4m3wQgQ
 
         
         
         
         
         
         
         
         
                         
                         
                         
                         
                         
                         
                         
                         
                         
                         
                        